Deal Ends Today·Save 35% annual plan
GIP/GLP-1 receptor agonistReviewed for 2026 plan year

Does Humana Cover Mounjaro?

The verdict

Conditional on most plans

Humana covers Mounjaro for type 2 diabetes under Medicare Part D and Medicaid with prior authorization. Mounjaro is not covered for weight loss under any Humana line. Critically, Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge — which Humana itself administers — because the Bridge covers only weight-loss-approved products (Wegovy, Foundayo, Zepbound KwikPen). For weight loss, the same molecule (tirzepatide) is Zepbound, with separate coverage.

MedicareConditional
CommercialConditional
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Humana using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Humana drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • The 2026 Medicare GLP-1 Bridge ($50/month copay, administered by Humana) covers Wegovy, Foundayo, and the Zepbound KwikPen only — Mounjaro is excluded because it is a diabetes drug, not a weight-loss drug.

    CMS.gov, Medicare GLP-1 Bridge Demonstration, 2026

  • The 2026 Part D out-of-pocket cap is $2,100. Most Humana Part D enrollees taking Mounjaro continuously for diabetes reach the cap within 2-3 months and pay $0 for the rest of the year.

    CMS.gov, Medicare Part D Redesign 2025-2026

  • The IRA-negotiated Medicare MFN price for Mounjaro (tirzepatide) is $245/month, effective mid-2026 for Medicare enrollees.

    CMS.gov, IRA Drug Price Negotiation Program, 2026

Plan types

Medicare vs. commercial coverage

Whether Humana covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Conditional

Humana Medicare Part D and Medicare Advantage plans cover Mounjaro for type 2 diabetes only — not weight loss — at a specialty or non-preferred tier, with prior authorization. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2-3 months, then pay $0 for the rest of the year. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month, July 1, 2026 – December 31, 2027). Although Humana is CMS's selected central processor for administering the Bridge, the Bridge explicitly covers weight-loss-approved products only (all Wegovy formulations, Foundayo, and the Zepbound KwikPen). Mounjaro is excluded because it is a diabetes drug. The Lilly savings card is not usable by Medicare or Medicare Advantage beneficiaries.

Commercial / Employer

Group & marketplace plans

Conditional

Humana has a limited commercial and employer-sponsored book of business. Where commercial coverage is offered, Mounjaro is covered for type 2 diabetes with prior authorization; weight-loss use is excluded. ACA/Individual: Humana has a limited ACA marketplace presence; Mounjaro is covered for T2D with PA where offered, and weight-loss GLP-1s are commonly excluded. Medicaid: Humana Medicaid managed-care plans cover Mounjaro for T2D with prior authorization and nominal cost-share per state PDL. Weight-loss GLP-1 coverage is not available under Humana Medicaid. The Lilly savings card is not available to Medicaid beneficiaries.

Prior authorization

The 5 boxes you must tick to get approved

Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 5

Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Approximately $1,300–$1,560/month retail (WAC ~$1,080). The Lilly savings card is not available to Medicare or Medicaid beneficiaries.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Medicare Part D: 25% coinsurance after deductible until the $2,100 out-of-pocket cap; most continuous users reach the cap within 2-3 months and pay $0 thereafter. MFN price of $245/month begins mid-2026 for Medicare. Medicaid: nominal cost-share per state PDL.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only and does not apply to Mounjaro.

Reduced copay through the assistance program, where eligible.

All figures are estimates; actual cost-share varies by plan and pharmacy. Confirm with your Humana plan's formulary or member services. The Lilly savings card applies only to commercially insured patients and expires 12/31/2026.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Check the Humana formulary for your specific plan

    Visit Humana.com and use the drug finder tool for your specific Medicare Part D, Medicare Advantage, or Medicaid plan. Enter 'Mounjaro' or 'tirzepatide' and confirm it is listed for diabetes (ICD-10 E11.x) on your plan's drug list. Note the tier and whether prior authorization is required.

  2. 2

    Work with your prescriber on the PA submission

    Your prescriber needs to document your confirmed T2D diagnosis, A1c of 6.5% or higher, and prior use of metformin or a documented contraindication. Humana's Part D coverage determination process requires this evidence. Submit the PA through your prescriber's office; allow up to 72 hours for standard review or 24 hours for urgent requests.

  3. 3

    Call Humana member services to confirm cost and Bridge eligibility

    Call the number on the back of your Humana card. Ask: Is Mounjaro covered for type 2 diabetes on my plan? What is my out-of-pocket cost-share? Am I enrolled in a plan that is part of the 2026 Medicare GLP-1 Bridge, and does the Bridge cover Mounjaro? (Answer to the last question: No — the Bridge excludes Mounjaro.)

If it's denied

Options if Humana won't cover Mounjaro

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Ozempic (semaglutide)

FDA-approved for type 2 diabetes. Often covered at a preferred or non-preferred brand tier on Humana Part D plans with prior authorization.

Trulicity (dulaglutide)

FDA-approved for T2D. GLP-1 alternative frequently at preferred tier on Humana formularies; lower list price than Mounjaro.

Jardiance (empagliflozin)

SGLT2 inhibitor approved for T2D with cardiovascular benefits. Often on preferred tiers for Humana Medicare and Medicaid plans.

Zepbound (tirzepatide) — weight loss only

Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and obstructive sleep apnea. NOT diabetes coverage. Zepbound is included in the 2026 Medicare GLP-1 Bridge ($50/month) for weight-loss indication; Mounjaro is not. Coverage requires a separate weight-loss indication approval.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

No. The 2026 Medicare GLP-1 Bridge — which Humana administers as the CMS-selected central processor — covers weight-loss-approved products only: all Wegovy formulations, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded from the Bridge because it is FDA-approved for type 2 diabetes, not weight loss. Medicare covers Mounjaro under standard Part D for diabetes only, with prior authorization and specialty-tier cost-share, subject to the $2,100 annual OOP cap.

No. Humana does not cover Mounjaro for weight loss under any line of business — Medicare Part D, Medicare Advantage, Medicaid, or commercial. Mounjaro is FDA-approved for type 2 diabetes only. Off-label weight-loss requests coded with obesity diagnoses are denied. For weight loss, the same active ingredient (tirzepatide) is available as Zepbound, which is FDA-approved for chronic weight management. Zepbound has separate and often-excluded coverage from Mounjaro.

Under the 2026 Medicare Part D redesign, you pay 25% coinsurance after your deductible until you hit the $2,100 annual out-of-pocket cap. Most continuous Mounjaro users for diabetes reach the cap within 2-3 months and pay $0 for the remainder of the year. Starting mid-2026, the IRA-negotiated Medicare MFN price of $245/month takes effect. The Lilly savings card is not available to Medicare or Medicare Advantage beneficiaries.

Humana's Part D prior authorization process requires a confirmed type 2 diabetes diagnosis (ICD-10 E11.x), A1c of 6.5% or greater, and documented trial or failure of metformin (and often one additional oral agent). Patient must be 18 or older. Quantity limit is typically 4 pens per 28 days. Your prescriber submits the PA on your behalf; verify the specific criteria and process on Humana's coverage determination portal.

Only if you have a Humana commercial plan (employer-sponsored), not Medicare or Medicaid. The Lilly Mounjaro Savings Card is explicitly unavailable to Medicare Part D, Medicare Advantage, Medicaid, Medicare Supplement/Medigap, DoD, VA, and TRICARE beneficiaries. Commercially insured Humana members with Mounjaro coverage may pay as little as $25/month; without coverage, $499/month (up to 13 fills, expires 12/31/2026).

The Curex GLP-1 program

Insurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance

Humana Medicare readers hoping Mounjaro is covered for weight loss will be denied — it is diabetes-only, and it is excluded from the 2026 GLP-1 Bridge. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.

Compounded semaglutide
from$49/mo
Weekly injection or oral tablet
Compounded tirzepatide
from$149/mo
Injection or oral tablet
  • Medication + free shipping
  • 24/7 provider access
  • Medical intake & prescription review
From $49/moNo insurance requiredNo prior auth
Build your personalized planPrescription required, subject to provider review.

Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Humana before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

Weight care with Curex

Insurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance

Build your personalized plan

Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.